Alefacept. Antipsoriatic

Drugs of the Future

Volumn 26, Issue 6, 2001, Pages 527-532

  Sorbera, L A ^a   Revel, L ^a   Fernandez R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BG 9273; BG 9712; CEDELIZUMAB; EFALIZUMAB; GALIXIMAB; HLA C ANTIGEN; HYBRID PROTEIN; IC 747; IMMUNOGLOBULIN G1; INTERLEUKIN 2 RECEPTOR ANTIBODY; IR 502; LPD 519; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY IDEC 131; SIPLIZUMAB; UNCLASSIFIED DRUG; VIDILIZUMAB; ZANOLIMUMAB;

ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; EFFECTOR CELL; INFLAMMATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PSORIASIS;

EID: 0034814214     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.06.627131     Document Type: Article

References (32)

1. Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein
2. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses
3. The cytokine network in psoriasis
4. Treatment of psoriasis
5. Cell kinetics in psoriasis: The use of animal and human skin models
6. Dermal injection of immunocytes induces psoriasis
7. Response of psoriasis to a new topical retinoid, AGN 190168
8. Changes in keratinocyte maturation during wound healing
9. Cellular actions of etretinate in psoriasis: Enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes
10. Psoriasis in monozygotic twins: Variations in expression in individuals with identical genetic constitution
11. The immunopathology of psoriasis
12. Epidermal T lymphocytes and HLA-DR expression in psoriasis
13. Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome
14. Cross-reactivity between streptococcal M surface antigen and human skin
15. Psoriasis: A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis
16. hu1124
17. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice
18. Immunomodulation by LFA3TIP, an LFA 3/IgG1 fusion protein: Cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers
19. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates
20. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival
21. The pharmacokinetic/pharmacodynamic (PK/PD) modeling of immunoglobulin fusion protein, LFA3TIP, using a non-linear saturable cell activity model
22. Pharmacokinetics of LFA3TIP, an immunoglobulin fusion protein, in male and female baboons
23. Pharmacokinetics of LFA3TIP, an immunoglobulin fusion protein, in normal healthy volunteers
24. Pharmacokinetics of LFA3TIP (Amevive) in chronic plaque psoriasis patients during repeated once-weekly intravenous administration
25. Immunopharmacologic effects of LFA3TIP: Selectivity for peripheral memory-effector (CD45RO) over naive (CD45RA+) T-cells and correlation with clinical outcome in chronic plaque psoriasis
26. The response of chronic plaque psoriasis to Amevive™ (LFA3TIP) and the selective suppression of peripheral memory/effector T cells (CD45RO+) verses naive T cells (CD45RA+) is linked to serum levels of LFA3TIP
27. Duration of clinical response of LFA3TIP in chronic plaque psoriasis: Results of a multi-center placebo-controlled trial
28. Pharmacodynamic effects of LFA3TIP (Amevive) in patients with chronic plaque psoriasis (CPP): Selective modulation of CD45RO+ lymphocytes
29. Safety and efficacy of retreatment with LFA3TIP in chronic plaque psoriasis
30. Biogen's Amevive successfully completes phase III trials